CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity.

MLA

Kathleen M C Sullivan, et al. “CCX559 Is a Potent, Orally-Administered Small Molecule PD-L1 Inhibitor That Induces Anti-Tumor Immunity.” PLoS ONE, vol. 18, no. 6, Jan. 2023, p. e0286724. EBSCOhost, https://doi.org/10.1371/journal.pone.0286724.

APA

Kathleen M C Sullivan, Marta Vilalta, Linda S Ertl, Yu Wang, Carolyn Dunlap, Karen Ebsworth, Bin N Zhao, Shijie Li, Yibin Zeng, Zhenhua Miao, Pingchen Fan, Venkat Mali, Christopher Lange, Darren McMurtrie, Ju Yang, Rebecca Lui, Ryan Scamp, Vicky Chhina, Alice Kumamoto, … Penglie Zhang. (2023). CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity. PLoS ONE, 18(6), e0286724. https://doi.org/10.1371/journal.pone.0286724

Chicago

Kathleen M C Sullivan, Marta Vilalta, Linda S Ertl, Yu Wang, Carolyn Dunlap, Karen Ebsworth, Bin N Zhao, et al. 2023. “CCX559 Is a Potent, Orally-Administered Small Molecule PD-L1 Inhibitor That Induces Anti-Tumor Immunity.” PLoS ONE 18 (6): e0286724. doi:10.1371/journal.pone.0286724.